Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP).
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
15 07 2021
15 07 2021
Historique:
received:
17
01
2021
accepted:
05
04
2021
pubmed:
17
5
2021
medline:
11
8
2021
entrez:
16
5
2021
Statut:
ppublish
Résumé
To characterize their potential use in pre-exposure prophylaxis (PrEP) we compared the pharmacokinetics of raltegravir and lamivudine in genital tissue against ex vivo tissue infection with HIV-1. Open-label trial of 36 HIV-negative females and males randomized to 7 days raltegravir 400 mg twice daily and 7 days raltegravir 400 mg+lamivudine 150 mg twice daily (after washout), or vice versa. Blood, saliva, rectal fluid, rectal tissue, vaginal fluid and vaginal tissue were sampled at baseline and on and off PrEP during a total of 12 days, for pharmacokinetics and antiviral activity via ex vivo HIV-1BaL challenge. Ex vivo infectivity was compared with baseline. The trial has been registered in https://clinicaltrials.gov/ with the identifier NCT03205566. Steady state for both drugs was reached by day 4. Dosing with raltegravir alone provided modest ex vivo HIV protection with higher drug levels in rectal tissue and vaginal tissue than in plasma on and off PrEP. Off PrEP, plasma and vaginal concentrations declined rapidly, while persisting in the rectum. On PrEP, the highest lamivudine concentrations were in the rectum, followed by vaginal tissue then plasma. Lamivudine washout was rapid in plasma, while persisting in the rectum and vagina. Raltegravir/lamivudine increased ex vivo protection on and off PrEP compared with raltegravir alone, reaching maximum protection at day 2 in rectal tissue and at day 8 in vaginal tissue. Raltegravir 400 mg+lamivudine 150 mg showed high levels of ex vivo HIV protection, associated with high drug concentrations persisting after discontinuation in vaginal and rectal compartments, supporting further investigation of these agents for PrEP.
Sections du résumé
BACKGROUND
To characterize their potential use in pre-exposure prophylaxis (PrEP) we compared the pharmacokinetics of raltegravir and lamivudine in genital tissue against ex vivo tissue infection with HIV-1.
METHODS
Open-label trial of 36 HIV-negative females and males randomized to 7 days raltegravir 400 mg twice daily and 7 days raltegravir 400 mg+lamivudine 150 mg twice daily (after washout), or vice versa. Blood, saliva, rectal fluid, rectal tissue, vaginal fluid and vaginal tissue were sampled at baseline and on and off PrEP during a total of 12 days, for pharmacokinetics and antiviral activity via ex vivo HIV-1BaL challenge. Ex vivo infectivity was compared with baseline. The trial has been registered in https://clinicaltrials.gov/ with the identifier NCT03205566.
RESULTS
Steady state for both drugs was reached by day 4. Dosing with raltegravir alone provided modest ex vivo HIV protection with higher drug levels in rectal tissue and vaginal tissue than in plasma on and off PrEP. Off PrEP, plasma and vaginal concentrations declined rapidly, while persisting in the rectum. On PrEP, the highest lamivudine concentrations were in the rectum, followed by vaginal tissue then plasma. Lamivudine washout was rapid in plasma, while persisting in the rectum and vagina. Raltegravir/lamivudine increased ex vivo protection on and off PrEP compared with raltegravir alone, reaching maximum protection at day 2 in rectal tissue and at day 8 in vaginal tissue.
CONCLUSIONS
Raltegravir 400 mg+lamivudine 150 mg showed high levels of ex vivo HIV protection, associated with high drug concentrations persisting after discontinuation in vaginal and rectal compartments, supporting further investigation of these agents for PrEP.
Identifiants
pubmed: 33993302
pii: 6276547
doi: 10.1093/jac/dkab136
pmc: PMC8325523
doi:
Substances chimiques
Anti-HIV Agents
0
Lamivudine
2T8Q726O95
Raltegravir Potassium
43Y000U234
Banques de données
ClinicalTrials.gov
['NCT03205566']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2129-2136Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
N Engl J Med. 2012 Aug 2;367(5):423-34
pubmed: 22784038
AIDS. 2011 Oct 23;25(16):1971-9
pubmed: 21811139
J Virol. 2001 Sep;75(18):8390-9
pubmed: 11507184
J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jun 1;878(19):1455-65
pubmed: 20427248
Cold Spring Harb Perspect Med. 2012 Nov 01;2(11):
pubmed: 23043157
AIDS Res Hum Retroviruses. 2012 Nov;28(11):1422-33
pubmed: 22900504
J Antimicrob Chemother. 2015 May;70(5):1473-81
pubmed: 25630643
Science. 1986 Jul 11;233(4760):215-9
pubmed: 3014648
Curr Top Microbiol Immunol. 2014;383:1-25
pubmed: 23612992
J Acquir Immune Defic Syndr. 2020 Apr 15;83(5):530-537
pubmed: 32168200
J Clin Microbiol. 2009 Nov;47(11):3530-9
pubmed: 19726602
J Virol. 2009 Sep;83(18):9175-82
pubmed: 19587055
N Engl J Med. 2012 Aug 2;367(5):411-22
pubmed: 22784040
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
PLoS Med. 2008 Aug 5;5(8):e157; discussion e157
pubmed: 18684007
Clin Infect Dis. 2015 Aug 15;61(4):572-80
pubmed: 25908682
PLoS One. 2010 Dec 21;5(12):e15257
pubmed: 21203568
AIDS. 2013 Jun 1;27(9):1413-9
pubmed: 23945503
Clin Pharmacokinet. 2014 Jul;53(7):611-24
pubmed: 24859035
Virology. 2016 Feb;489:173-8
pubmed: 26771889
PLoS One. 2014 Oct 28;9(10):e111507
pubmed: 25350130
Curr Opin HIV AIDS. 2020 Jan;15(1):19-26
pubmed: 31644481
J Exp Med. 2004 Apr 19;199(8):1065-75
pubmed: 15078900
J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):252-257
pubmed: 27727157
Antiviral Res. 2010 Jun;86(3):312-5
pubmed: 20302887
Curr Opin HIV AIDS. 2012 Sep;7(5):390-400
pubmed: 22789987
AIDS. 2019 Feb 1;33(2):237-246
pubmed: 30557160
AIDS Res Hum Retroviruses. 2012 Nov;28(11):1412-21
pubmed: 22943559
N Engl J Med. 2015 Dec 3;373(23):2237-46
pubmed: 26624850
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
Antimicrob Agents Chemother. 2009 May;53(5):1797-807
pubmed: 19258271
PLoS One. 2015 May 05;10(5):e0125363
pubmed: 25942472
J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):261-4
pubmed: 21546848
Antivir Ther. 2011;16(8):1149-67
pubmed: 22155899
PLoS Pathog. 2012;8(12):e1003071
pubmed: 23236282